This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
PALO ALTO, Calif., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today that company management plans to present at the Cowen Health Care Conference. Ocera's presentation is scheduled for Wednesday, March 5, 2014 at 8:00 AM ET.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website,
www.ocerainc.com . Please connect to the website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
A replay of the webcast can be accessed for a minimum of one month and will be available approximately 24 hours after the live presentation on
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger under development for the treatment of hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. The FDA has granted Orphan Disease and Fast Track status to OCR-002. For additional information, please see
Ocera Therapeutics, Inc.